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Abstract 
Background: Diabetic cardiomyopathy (DCM), a fatal cardiovascular complication of diabetes mellitus, often leads 
to progressive heart failure, however its pathogenesis remains unclear. Corin, a cardiac serine protease, is responsible 
for converting pro-atrial natriuretic peptide (pro-ANP) to biologically active atrial natriuretic peptide (ANP). It has been 
well established that corin deficiency is associated with the progression of hypertension, cardiac hypertrophy and 
heart failure. However, because the involvement of corin-mediated pro-ANP processing in DCM has not been clarified, 
this study aims to investigate the role of corin in the pathogenesis of DCM.
Methods: Diabetes mellitus was induced by a single intraperitoneal injection of streptozotocin (STZ 65 mg/kg) to 
Sprague–Dawley rats (180–220 g). DCM was confirmed by monitoring continuously transthoracic echocardiography 
every 4 weeks and hemodynamic measurements at 20 weeks. Myocardial disorder and fibrosis were detected by 
HE staining and Masson’s trichrome staining. The mRNA and protein levels of corin and ANP in rat hearts and car-
diomyocytes were determined by quantitative real-time PCR, western blotting and immunohistochemical staining, 
respectively. H9c2 cardiomyoblasts proliferation was detected by MTT colorimetric assay and viable cell counting with 
trypan blue. The effect of Corin-siRNA H9c2 cardiomyoblasts on EA.hy926 cells migration was measured by the wound 
healing scratch assay.
Results: The corin and ANP expression in mRNA and protein levels was decreased in DCM rat hearts. Corin and ANP 
levels of neonatal rat cardiomyocytes and H9c2 cardiomyoblasts treated with high glucose were significantly lower 
than that of normal glucose treated. Precisely, corin and ANP levels decreased in DCM rats at 12, 16, 20 and 33 weeks; 
neonatal cardiomyocytes and H9c2 cardiomyoblasts treated with high glucose at 36, 48 and 60 h demonstrated sig-
nificant reduction in corin and ANP levels. Corin-siRNA H9c2 cardiomyoblasts showed decreased proliferation. Culture 
supernatants of Corin-siRNA H9c2 cardiomyoblasts prevented endothelial cell line EA.hy926 migration in the wound 
healing scratch assay. Furthermore, iso-lectin expression in arteriole and capillary endothelium was down-regulated in 
DCM rats.
Conclusions: Our results indicate that corin plays an important role in cardioprotection by activating pro-atrial 
natriuretic peptide pathway in DCM. Corin deficiency leads to endothelial dysfunction and vascular remodeling.
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Background
Diabetes mellitus (DM) is a chronic, complex disease. 
The prevalence of diabetes mellitus worldwide contin-
ues to increase. The total number of people with diabetes 
mellitus is estimated to rise from 135 million in 1995 to 
300 million in 2025 [1]. Diabetic cardiomyopathy (DCM) 
is a major cardiovascular complication of diabetes, and 
the leading cause of heart failure and death [2]. DCM 
is characterized by its effects on cardiac structures and 
function in the absence of hypertension and coronary 
artery diseases [3]. However, to date, knowledge in the 
pathogenesis of DCM is still limited.
Genetic studies have shown that the human CORIN 
gene encodes a type II transmembrane serine protease 
called corin, which is primarily expressed in cardiac tis-
sue. Corin acts as an enzyme in the processing of atrial 
natriuretic peptide hormone, converting pro-atrial 
natriuretic peptide (pro-ANP) to biologically active atrial 
natriuretic peptide (ANP) [4–7]. ANP is a cardiac hor-
mone essential for the regulation of blood pressure by 
promoting salt excretion, decreasing blood volume, and 
relaxing vascular smooth muscles [8]. In mice, corin defi-
ciency is associated with hypertension and cardiac hyper-
trophy [9]; reduced sodium excretion and salt-sensitive 
hypertension are seen in corin knockout mice due to 
impaired natriuretic peptide processing [10]. Clinically, 
patients with heart failure often have decreased plasma 
corin level [11]. From these studies, we can see that corin, 
undoubtedly, takes on an important role in the develop-
ment of cardiovascular diseases.
Endothelial dysfunction and vascular remodeling are 
associated with both diabetes mellitus and diabetic car-
diomyopathy [12, 13]. Our previous study indicates that 
corin could promote uterine spiral artery remodeling 
[14]. While, ANP and its downstream molecules could 
induce endothelial cell proliferation, migration and 
regeneration after vascular injury [15, 16]. Therefore we 
speculate that corin may be involved in the pathogen-
esis of diabetic cardiomyopathy through activation of 
pro-ANP.
In this study, we used streptozotocin (STZ)-induced 
diabetes animal model, high glucose-induced neona-
tal rat cardiomyocytes and H9c2 cardiomyoblasts to 
detect corin and ANP expression in  vivo and in  vitro. 
At the same time, we investigated the effect of Corin-
siRNA H9c2 cardiomyoblasts culture supernatants on 
EA.hy926 cells migration by wound healing scratch 
assay. Our results indicated that corin exerted cardio-
protective action via pro-ANP activating pathway in 
DCM, meanwhile, corin deficiency was associated with 
endothelial dysfunction and vascular remodeling.
Methods
Induction of the diabetes model
Forty-five male Sprague–Dawley rats (180–220  g) were 
purchased from the experimental animal center of Acad-
emy of Military Medical Sciences (Beijing, China). The 
animals were housed at 22 ±  2  °C with 12 h light–dark 
cycles. All care and experimental procedures of animals 
were in accordance with the guidelines for the Care and 
Use of Laboratory Animals published by the National 
Institute of Health and approved by the Animal Care & 
Welfare Committee of Tianjin Medical University. The 
rats were randomly divided into two groups: control 
group and diabetes group. Diabetes group was induced 
by a single intraperitoneal injection of STZ (Sigma; 
65  mg/kg dissolved in 0.1  mol/L citrate buffer, pH 4.5). 
The control group received the same dose of citrate buffer 
alone. The two groups received normal chow. Blood glu-
cose levels were measured on day 3 and 7 after STZ or 
citrate buffer administration by a hand-held glucometer 
(UltraEasy, Johnson, USA). Rats with random blood glu-
cose (RBG) >16.7 mM in two consecutive examinations 
were considered as diabetic model. We monitored body 
weight, blood glucose, and urine glucose every week. The 
two groups were sacrificed under deep anesthesia (a sin-
gle intraperitoneal injection of 3 % sodium pentobarbital 
at the dose of 50 mg/kg body weight) by exsanguinations.
Echocardiography and hemodynamic measurements
Transthoracic echocardiography was performed by the 
vivid 3 pro imaging system (GE, USA) in both groups at 
4, 8, 12, 16, 20  weeks. Images were obtained from two-
dimensional, M-mode, pulsed-wave Doppler imaging. All 
measurements were the average of six consecutive car-
diac cycles and performed by the same operator. Briefly, 
male SD rats were lightly anaesthetized with 3 % inhaled 
isoflurane and set in a supine position. The hemithorax 
of each rat was carefully shaved. Diastolic interventricu-
lar septal wall thickness (IVSd), left ventricular posterior 
wall thickness in diastole (LVPWd), left ventricular inter-
nal dimension in diastole (LVIDd), left ventricular inter-
nal dimension in systole (LVIDs), fractional shortening 
(FS %) and left ventricular ejection fraction (EF %) were 
measured. Mean arterial blood pressure (MABP), maxi-
mal rate of rise in LV pressure (+dP/dt), and maximal 
rate of decline in LV pressure (−dP/dt) of DCM and Ctrl 
rats at 20 weeks were measured with a manometer-tipped 
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catheter (SPR-320NR, Millar, USA) and recorded by an 
MP150 system (Biopac Systems, USA).
Histology and immunohistochemistry
Paraformaldehyde (4  %)-fixed hearts were embedded 
in paraffin, and cut into 5  μm sections. The extent of 
myocyte hypertrophy was evaluated by hematoxylin-
eosin staining. Interstitial and perivascular fibrosis were 
evaluated by Masson’s trichrome staining. For immu-
nohistochemical staining, sections were incubated with 
anti-corin (sc-67179, Santa Cruz Biotechnology Inc.) 
or anti-ANP (sc-18811, Santa Cruz Biotechnology Inc.) 
antibody and a secondary antibody conjugated with HRP 
(horseradish peroxidase). Nuclei were counterstained 
with haematoxylin. Immuno-reactivity was demonstrated 
by 3, 3′-diaminobenzidine (DAB, BOSHIDE). Data were 
collected from at least five rats per study group.
Immunofluorescent studies were carried out in neo-
natal rat cardiomyocytes and H9c2 cardiomyoblasts on 
glass coverslips. The antibodies used were as follows: 
anti-corin antibody (sc-67179, Santa Cruz Biotechnology 
Inc.), secondary antibody conjugated with FITC (Invitro-
gen). Capillary and arteriole densities were identified by 
immunofluorescent staining with iso-lectin B4. Nuclei 
were stained with DAPI (4′, 6-diamino-2-phenylindole, 
Invitrogen). Immunostaining images were examined 
under a confocal microscope (Leica).
Electron microscopy
Fresh tissues from SD rat left ventricular anterior wall 
were cut into about 1 mm3 blocks, fixed in 2.5 % glutaral-
dehyde, 0.1 M cacodylate buffer solution for 24 h at 4 °C, 
and then embedded in an Araldite-Epon812 mixture. 
Ultrathin sections  (50  nm) were prepared and stained 
with uranyl acetate and lead citrate. The sample slices 
were examined using a transmission electron microscope 
(Hitachi, Japan).
Isolation and culture of neonatal cardiomyocytes
Neonatal rat cardiomyocytes were acquired from the 
neonate rats (within 48 h). All experimental procedures 
were approved by the Animal Care & Welfare Committee 
of Tianjin Medical University. Neonatal rats were decapi-
tated, a midline incision was made through the sternum. 
The hearts were gently taken out, atriums were cut off. 
Then ventricles were cutted into 1–1.5  mm3 pieces and 
digested by 7–8  ml 0.125  % trypsin. The enzyme diges-
tion process was performed for 5–7  min each time and 
repeated about 8 times until all the tissue blocks were 
digested. Trysinization was terminated with FBS (FBS: 
trypsin = 1:10). The cell suspensions were centrifuged at 
192×g for 8  min at 4  °C and resuspended with DMEM 
containing 10 % FBS. Collected cells were incubated for 
1.5  h differential attachment in DMEM with 10  % FBS 
to reduce non-myocyte contamination, appropriate 
5-bromo-2-deoxyuridine was added into the remaining 
cell suspension, and followed by cultured in 6-well col-
lagen-coated plates. Cardiomyocytes were treated with 
various glucose levels: 5.5  mM glucose (Ctrl, normal 
glucose), 5.5  mM glucose plus 19.5  mM mannose (OC, 
osmotic control) and 25 mM glucose (HG, high glucose). 
After incubation at 37 °C for 36, 48, 60 h, cells were har-
vested for either western blot or real-time qPCR.
Measurement of mRNA by Reverse transcription 
polymerase chain reaction (RT‑PCR) and quantitative 
real‑time PCR
Total RNA was isolated from rat hearts or cultured cardio-
myocytes by using TRIzol reagent (Invitrogen). Reverse tran-
scription was performed using FastQuant RT kit (Tiangen, 
China). The products of RT-PCR for corin and ANP mRNA 
expression in rat hearts were detected by agarose gel electro-
phoresis. Real-time qPCR for corin and ANP mRNA expres-
sion in rat hearts and cardiomyocytes was performed using 
the Stratagene Mx3005P (Agilent Technologies) following 
the manufacturer’s protocol. PCR cycling conditions: 95 °C 
for 15 min, followed by 40 cycles of 95 °C (10 s), 58 °C (20 s), 
and 72 °C (30 s). PCR products were confirmed by melting 
curve analysis using the MxPro QPCR Software. The rela-
tive expression of the genes was analyzed with the 2−ΔΔCt 
method. The specific primer sequences were given below: 
5′-TGCCCAAGCGGAAGTGAG-3′ and 5′-GACGGATGG 
TCCAGGTTGTTT-3′ for corin; 5′-GTACAGTGCGGT 
GTCCAACA-3′ and 5′-ATCCTGTCAATCCTACCCCC-3′ 
for ANP; 5′-GGGTGTGAACCACGAGAAAT-3′ and 5′-AC 
TGTGGTCATGAGCCCTTC-3′ for GAPDH; 5′-GTTGA 
CATCCGTAAAGACC-3′ and 5′-GACTCATCGTACTCCT 
GCT-3′ for β-actin. The housekeeping gene GAPDH or 
β-actin was used as an internal control. All of the tests were 
measured in duplicate.
Western blot analysis
Rat hearts were homogenized in a lysis buffer contain-
ing 20  mmol/L Tris–HCl (pH 8.0), 100  mmol/L NaCl, 
1  mmol/L EDTA, 10  % NP-40 (vol/vol) and a protease 
inhibitor cocktail (1:100 dilution, Sigma). Proteins from 
neonatal rat cardiomyocytes and H9c2 cardiomyoblasts 
were prepared by adding RIPA buffer (P0013B, Beyo-
time Biotechnology, China) supplemented with a pro-
tease inhibitor cocktail. Total protein concentrations 
were measured using a BCA protein assay kit (Pierce, 
Thermo). Equal amounts of total extracted proteins from 
rat hearts (100 μg) or cardiomyocytes (40 μg) were sepa-
rated by SDS-polyacylamide agarose gel electrophore-
sis (SDS-PAGE) and transferred electrophoretically to 
polyvinylidene difluoride (PVDF) membranes (Millipore, 
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USA). The blots were subjected to immunoblot analysis 
with the primary antibodies and then incubated with 
secondary HRP-conjugated IgG antibodies. The bands 
were visualized using enhanced chemiluminescence rea-
gent kit (Millipore, USA). Corin antibody was a gift from 
Dr. Ningzheng Dong (Cyrus Tang Hematology Center, 
Jiangsu Institute of Hematology). The other antibodies 
were as follows: ANP antibody (sc-18811, Santa Cruz 
Biotechnology Inc.), internal control β-actin (sc-47778, 
Santa Cruz Biotechnology Inc.). The band intensities 
were quantified by image J Acquisition and Analysis 
Software.
Enzyme‑linked immunosorbent assay for N‑terminal 
pro‑ANP (NT‑proANP) in plasma of rats
Plasma NT-proANP level was measured by ELISA kit 
(ALPCO, USA). The assay was performed according 
to manufacturer’s instructions. The concentrations of 
NT-proANP (ng/mL) were detected at 450 nm by spec-
trophotometry (Bio-Tek Synergy 2, USA) and were cal-
culated by comparing the OD value of the samples to a 
standard curve. Results were converted to nmol/L and 
expressed as concentrations relative to the correspond-
ing control group. All of the samples were measured in 
duplicate.
Transfection of Corin‑siRNA into H9c2 cardiomyoblasts
Transfections were performed with lipo3000 (invit-
rogen, USA) according to the manufacturer’s instruc-
tions. Specific Corin-siRNA sequences were synthesized 
(genepharma, China) and transfected into H9c2 car-
diomyoblasts. The sense and antisense strands of Corin-
siRNA sequence 1 were 5′-GCAGUGUAAUGGCUACAA 
UTT-3′ and 5′-AUUGUAGCCAUUACACUGCTT-3′. The 
sense and antisense strands of Corin-siRNA sequence 2 
were 5′-GUGGACAUUAUUUGGUUUATT-3′ and 5′-UA 
AACCAAAUAAUGUCCACTT-3′. H9c2 cardiomyo-
blasts were transfected for 48  h, the efficiency of corin 
silencing was assessed by real-time qPCR and western 
blot analysis. Data were from at least seven dependent 
experiments.
Proliferation assay
Cell proliferation was detected by MTT colorimet-
ric assay and viable cell counting with trypan blue. The 
experiments were repeated three times at least.
MTT colorimetric assay: The H9c2 cardiomyoblasts 
were cultured in 96-well plates with DMEM containing 
10 % FBS. Corin-siRNA or negative control-siRNA (NC-
siRNA) was transfected into H9c2 cardiomyoblasts, 48 h 
later 20 μL of 5 mg/mL MTT solution was added to each 
well. Cells were cultured for 4 h at 37 °C, then followed by 
adding 150 μL DMSO. Absorbance value was detected at 
490 nm by a microplate reader (Bio-Tek Synergy 2, USA).
Viable cell counting with trypan blue: The H9c2 car-
diomyoblasts were cultured in 6-well plates with DMEM 
containing 10  % FBS. Corin-siRNA or NC-siRNA H9c2 
cardiomyoblasts were trypsinized, cell suspension and 
trypan blue were mixed with 9:1 and viable cells were 
counted by a haemocytometer.
The wound healing scratch assay
Scratch test was applied to detect the migration and 
wound healing of EA.hy926 cells. When the cells reached 
80  % confluence in 6-well plates, parallel streaks were 
created by scraping the confluent cell monolayer with a 
200 μL sterile pipette tip, then washed three times with 
PBS. H9c2 cardiomyoblasts were transfected with spe-
cific Corin-siRNA or NC-siRNA for 48 h, culture super-
natants were added into EA.hy926 cells. The cells were 
cultured at 37 °C in 5 % CO2 and pictures of the parallel 
lines were taken respectively at 0 and 24 h after scratch-
ing under the light microscope. The assay was done in 
duplicate in each group from at least three dependent 
experiments.
Statistical analysis
All  values  are  presented  as  mean  ±  SD. Western blot 
densities were analyzed with image J Acquisition and 
Analysis Software. All histopathological sections were 
analyzed by an imaging analysis system (NIH). Data 
between two groups were assessed by unpaired t-tests. 
Comparisons for three or more groups were done using 
one-way ANOVA or two-way ANOVA followed by Fish-
er’s LSD test. Statistical analysis was carried out using the 
GraghPad Prism software (version 6.01; GraghPad Prism 
Software, San Diego, CA, USA). P values less than 0.05 
were considered to be statistically significant.
Results
Characteristics of rats with STZ‑induced diabetic 
cardiomyopathy
DCM rats presented higher blood glucose (22.4–
33.3  mmol/L), while that of control group was main-
tained at normal level (Fig.  1a). Body weights were 
decreased in DCM rats compared with those in the 
control group at the same point in time (Fig.  1b). The 
urine glucose test of DCM rats was consistently positive 
(Data were not shown). At the same time, haematoxy-
lin eosin staining showed cardiomyocyte hypertrophy 
and masson’s trichrome staining displayed interstitial 
and perivascular fibrosis in DCM rats (Fig. 1c–e). Heart 
weight to body weight ratio was significantly increased 
in DCM rats in comparison to that in the control group 
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(Fig.  1f ). The changes of cardiac structure and cardiac 
dysfunction were assessed by echocardiography (Fig. 1g–
m) and hemodynamic measurements (Fig. 1n–p) in two 
groups. DCM rats showed impairment of cardiomyo-
cyte including severe mitochondria damage, disordered 
myofibrils arrangement (Fig. 2) and excess glycogen dep-
osition (Additional file 1: Figure S1) by transmission elec-
tron microscopy.
Corin and ANP levels were decreased in diabetic 
cardiomyopathy rats
To investigate whether corin and ANP were involved in 
the progression of DCM, we detected cardiac corin and 
ANP expression in rats. Reduced corin and ANP expres-
sion in mRNA (Fig.  3a–c) and protein (Fig.  3d–f) lev-
els was observed in DCM rats when compared with the 
control group. Precisely, we found decreased corin and 
ANP levels in DCM rats at 12, 16, 20, 33 weeks (Fig. 3g) 
whereas corin and ANP expression in the control rats 
remained constant (Fig.  3h). Furthermore, immunohis-
tological analysis demonstrated attenuation of corin and 
ANP expression in DCM rats myocardial pathological 
sections (Fig. 3i–k). Moreover, we found that plasma NT-
proANP level in DCM rats was much higher than that in 
control group (Fig. 3l). These results indicated that corin 
was involved in cardioprotection through activation of 
pro-ANP in DCM.
The expression of corin and ANP was reduced in high 
glucose‑induced neonatal rat cardiomyocytes and H9c2 
cardiomyoblasts
To further confirm the possible roles of corin and ANP, 
we next determined corin and ANP expression in vitro. 
In high glucose-induced neonatal rat cardiomyocytes, 
corin and ANP expression in mRNA and protein lev-
els was reduced compared with the control group 
(Fig.  4a–e). Furthermore, corin and ANP protein levels 
were decreased after neonatal rat cardiomyocytes were 
treated with high glucose for 36, 48, 60  h (Fig.  4f–h). 
These results indicated that the levels of corin and ANP 
in neonatal rat cardiomyocytes were decreased in a time-
dependent manner by high glucose treatment. While 
high osmolarity in neonatal rat cardiomyocytes had no 
effect on corin and ANP expression (Additional file  1: 
Figure S2). Immunofluorescence staining also showed 
that corin expression in high ambient glucose-induced 
neonatal rat cardiomyocytes was lowered (Fig. 4i). Mean-
while, parallel phenomenon could be also observed in 
H9c2 cardiomyoblasts (Fig.  4j–l). These data were con-
sistent with the observed corin and ANP expression in 
DCM rats, suggesting that high glucose level down-reg-
ulated expression of corin and ANP in cardiomyocytes.
Corin played a protective role in cardiomyocytes
To explore the exact role of corin in the development 
of diabetic cardiomyopathy, we inhibited corin expres-
sion by gene silencing of corin. The silencing efficiency 
of Corin-siRNA sequence 1 and 2 into H9c2 cardiomyo-
blasts reached about 55  % by real-time qPCR (Fig.  5a). 
We further verified that the Corin-siRNA sequences 
in H9c2 cardiomyoblasts were effective by western blot 
(Fig.  5b). Corin-siRNA H9c2 cardiomyoblasts prolifera-
tion was inhibited by morphological observation (Fig. 5c). 
Moreover, we found that the lack of corin significantly 
decreased cell viability and proliferation in H9c2 cardio-
myoblasts when compared with that in the control group 
using MTT colorimetric assay (Fig.  5d) and viable cell 
counting with trypan blue (Fig.  5e). These data showed 
that the cardioprotective effect of corin was attenuated in 
H9c2 cardiomyoblasts transfected with Corin-siRNA.
Defect of corin was associated with endothelial 
dysfunction and vascular remodeling
To determine the relationship between corin expression 
and endothelial function, we further detected the effect 
of Corin-siRNA H9c2 cardiomyoblasts on EA.hy926 cells 
migration. The migratory speed of EA.hy926 cells treated 
with culture supernatants of Corin-siRNA H9c2 cardio-
myoblasts was markedly decreased compared with that in 
NC-siRNA group using the wound healing assay (Fig. 6a). 
These results demonstrated the ability of corin to protect 
against endothelial dysfunction in  vitro. Furthermore, 
iso-lectin B4 expression in DCM rats was lower than that 
in the control group (Fig. 6b, c). These findings suggested 
that the lack of corin impaired endothelial function and 
ultimately led to vascular remodeling.
Discussion
In the present study, we demonstrated that cardiac corin 
expression was decreased in rat DCM models. In addi-
tion, downregulation of corin in mRNA and protein lev-
els impaired pro-ANP activating pathway, which led to 
ANP decline in the DCM hearts. Similar findings were 
shown in high glucose-induced neonatal rat cardiomyo-
cytes and H9c2 cardiomyoblasts. These results suggested 
that hyperglycemia inhibited corin-mediated pro-ANP 
processing in DCM. At the same time, we observed that 
corin deficiency inhibited H9c2 cardiomyoblasts prolif-
eration and impaired EA.hy926 cells function. This is a 
novel insight that corin plays a protective role and could 
maintain endothelial function in DCM.
In our STZ-induced DCM model, plasma glucose lev-
els were increased and hyperglycemia was maintained for 
a long period of time. Meanwhile, DCM rat hearts exhib-
ited cardiac dysfunction, cardiac hypotrophy, disordered 
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Fig. 1 General characteristics of diabetic cardiomyopathy (DCM) and control (Ctrl) rats. a Random blood glucose levels (n = 22 to 23 rats for 
each group). b Body weight levels (n = 21 to 23 rats for each group). c Cross (c1) and longitudinal (c2) sections of heart tissues were stained with 
haematoxylin and eosin (H&E). LV myocyte cross-sectional area was increased in DCM rats in comparison to that in the control group. Bar 30 μm. 
d Masson’s trichrome staining showed cardiac interstitial and perivascular fibrosis in DCM rats. Bar 30 μm. e Perivascular collagen area to lumen 
area ratio (PVCA/LA) for quantification of Masson’s trichrome staining. Three randomly selected fields from each rat myocardial tissue under ×400 
magnification were analyzed using NIH image software (n = 5 rats for each group). f Heart weight to body weight ratio (HW/BW, n = 22 rats for 
each group). g–m Echocardiographic findings of heart in Ctrl and DCM groups (n = 15 rats for each group). Values are mean ± SD. *P < 0.05 and 
**P < 0.01 versus Ctrl by two-way ANOVA. g Representative images of M-mode echocardiograms. h Diastolic interventricular septal wall thickness 
(IVSd). i Left ventricular posterior wall thickness in diastole (LVPWd). j Left ventricular internal dimension in diastole (LVIDd). k Left ventricular internal 
dimension in systole (LVIDs). l Fractional shortening (FS %). m Left ventricular ejection fraction (EF %). n–p The hemodynamic parameters of heart in 
DCM and Ctrl groups (n = 11 rats for each group). n Mean arterial blood pressure (MABP). o Maximal rate of rise in LV pressure (+dP/dt). p Maximal 
rate of decline in LV pressure (−dP/dt). Data are presented as mean ± SD. * P < 0.05 and ** P < 0.01 versus Ctrl
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arrangement of muscle fibers, cardiac interstitial and 
perivascular fibrosis.
Role of corin in the development of cardiovascular 
and other diseases
In our study, cardiac corin expression was reduced in 
both mRNA and protein levels in DCM rats. Consist-
ent with vivo study, corin expression was reduced in 
high glucose-induced neonatal cardiomyocytes and 
H9c2 cardiomyoblasts. Thus, we hypothesized that 
defect of corin may be a contributing factor in DCM. 
Similar findings of reduced corin level in other cardio-
vascular diseases have been reported in several stud-
ies. Corin deficiency exhibited cardiac hypertrophy 
and might contribute to hypertensive heart disease in 
mice [9]. Thomas et  al. found that atrial corin mRNA 
expression was downregulated in rats with heart failure 
[17]. Plasma corin level was reduced in decompensated 
heart failure patients [11]. Additionally, corin variant 
impaired pro-ANP processing, leading to cardiac hyper-
trophy and hypertension [18]. Low serum corin level 
predicted adverse cardiovascular prognosis in patients 
with acute coronary syndrome or after coronary artery 
bypass grafting surgery [19, 20]. Together, these findings 
suggested that corin played a cardiac protection effect. 
In supporting this hypothesis, corin overexpression was 
shown to improve cardiac function, heart failure, and 
survival in dilated cardiomyopathy mice [21]. How-
ever, Tarazón et al. reported that corin was elevated in 
heart transplant patients with ischemic cardiomyopa-
thy and LV concentration of corin was inversely related 
to left ventricular ejection fraction [22]. To this point, 
we speculate that several possibilities may exist. Firstly, 
corin expression may differ in different diseases (includ-
ing acute or chronic). Secondly, corin activity may not 
increase  even with elevated level of corin expression. 
Another study showed that cardiac corin expression was 
up-regulated but activity did not increase in late stages 
of HF patients and the mouse model of HF [23]. Finally, 
possible corin regulatory mechanisms may exist in car-
diac disease. Recently, Chen et  al. found that propro-
tein convertase subtilisin/kexin-6 (PCSK6, also named 
PACE4) could cleave and activate corin in hyperten-
sion [24]. We suppose that regulatory mechanisms for 
corin may differ in different cardiovascular diseases. At 
this time, the study of corin is limited, future studies 
on corin activation will help to better understand corin 
expression and activity.
Besides cardiovascular diseases, corin is also involved 
in other diseases. Serum corin levels are reduced in 
patients with nephrotic syndrome and glomerular dis-
ease, osteoporosis and human small cell lung cancer 
(SCLC) [25–27]. Serum soluble corin level may be a 
marker or a risk factor for obesity [28]. These findings 
indicate that corin plays an important role in the devel-
opment of many diseases.
Role of ANP in the development of cardiovascular 
and metabolic diseases
ANP is a cardiac hormone that regulates sodium home-
ostasis and blood pressure. ANP can be cleaved from 
pro-ANP by corin. In this study, we found that cardiac 
ANP expression was decreased. It was consistent with 
corin downexpression in DCM rat hearts, high glucose 
induced neonatal cardiomyocytes and H9c2 cardiomyo-
blasts. Coupled with higher plasma NT-proANP lev-
els in DCM rats, these findings indicated that pro-ANP 
processing mediated by corin was impaired and cardio-
protection of ANP in DCM was attenuated. Similarly, 
Gutkowska et  al. showed that ANP was downregulated 
in the model of type 2 diabetes [29]. Wang et al. demon-
strated that overexpression of ANP slowed HF progres-
sion while improved cardiac remodeling and survival in 
mice with dilated cardiomyophathy [30]; Nakagawa et al. 
reported that inhibition of aldosterone/MR combined 
with augmentation of the cardiac ANP/GC-A signal-
ing could prevent the transition of compensated cardiac 
hypertrophy to HF [31]. ANP exerted protective action 
Fig. 2 Transmission electron microscopy of Ctrl and DCM rat 
hearts. Bar 400 nm (i, ii), bar 325 nm (ii, iv). i, iii The ultrastructure of 
cardiomyocyte in Ctrl rats showed typical symmetric myofibrils, clear 
outline of mitochondria, integrated mitochondrial membrane and 
well-organized cristae. ii, iv The ultrastructure of cardiomyocyte in 
DCM rats showed severe mitochondria damage, disordered myofi-
brils arrangement
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Fig. 3 The mRNA and protein levels of corin and ANP in the heart of DCM and Ctrl rats. a–c The mRNA levels of corin and ANP in hearts of the two 
groups. a RT-PCR analysis of corin and ANP expression. b, c Quantification for cardiac corin and ANP mRNA levels by real-time qPCR (n = 7 rats 
for each group in b, n = 6 rats for each group in c. d–f The protein levels of corin and ANP in DCM and Ctrl rats were determined by western blot 
(n = 7 rats for each group in e, n = 8 rats for each group in f). g, h Corin and ANP levels of DCM and Ctrl rats at 12, 16, 20, 33 weeks were measured 
by western blot. i–k Corin and ANP protein levels in two groups were evaluated by immunohistochemistry and densitometry analysis. For quanti-
fication, at least four randomly selected fields from each rat myocardial tissue under ×400 magnification were analyzed using NIH image software. 
Bar 30 μm (n = 4 rats for each group). l The levels of NT-proANP in the plasma of DCM and Ctrl rats were measured by ELISA (n = 15 rats for each 
group). Data are presented as mean ± SD. *P < 0.05 and **P < 0.01 versus Ctrl
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Fig. 4 The effect of high ambient glucose on corin and ANP expression in neonatal rat cardiomyocytes and H9c2 cardiomyoblasts. a, b Quantifi-
cation for corin (a) and ANP (b) mRNA levels in neonatal rat cardiomyocytes was measured by real-time qPCR, neonatal rat cardiomyocytes were 
treated with normal or high glucose for 36 h (n = 6 for each group in a, n = 5 for each group in b). c–e The corin and ANP protein levels of neonatal 
rat cardiomyocytes at 36 h were measured by western blot (n = 6 for each group in d, n = 5 for each group in e). f–h Corin and ANP expression 
in neonatal rat cardiomyocytes at different culture time (n = 4 for each group in g, n = 5 for each group in h). i Immunofluorescence analysis of 
corin expression in neonatal rat cardiomyocytes at 36 h was performed by confocal fluorescence microscope. Bar 40 μm. j Corin expression in H9c2 
cardiomyoblasts at 36 h was detected by real-time qPCR (n = 6 for each group). k Corin and ANP expression in H9c2 cardiomyoblasts at different 
culture time was determined by western blot. l Immunofluorescence analysis of corin in H9c2 cardiomyoblasts at 36 h was performed by confocal 
fluorescence microscope. Bar 80 μm. Ctrl: normal glucose, 5.5 mM glucose; OC: osmotic control, 5.5 mM glucose plus 19.5 mM mannitol; HG: high 
glucose, 25 mM glucose. Data are presented as mean ± SD. *P < 0.05 and **P < 0.01 versus Ctrl
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Fig. 5 The effect of corin deficiency on H9c2 cardiomyoblasts proliferation. a, b The silencing efficiency of Corin-siRNA sequence 1 and sequence 2 
in H9c2 cardiomyoblasts was measured by real-time qPCR (n = 6 in each group) and western blot, compared with negative control-siRNA (NC-siRNA) 
group. c Morphological alterations of H9c2 cardiomyoblasts proliferation after transfection 0 and 48 h. Bar 100 μm. d H9c2 cardiomyoblasts were 
transfected 48 h later, cell proliferation was assayed by MTT (n = 5 in each group). e Viable cell count was performed using trypan blue at 48 h. Data 
represents 3 replicates and 3 repeats. Data are presented as mean ± SD. *P < 0.05 and **P < 0.01 versus NC-siRNA
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against cardiac remodeling and ANP treatment attenu-
ated cardiac inflammation, fibrosis and hypertrophy [32]. 
These findings suggested that ANP exhibited cardiac pro-
tective on many cardiovascular and metabolic diseases. 
ANP is a useful biomarker in the diagnosis of cardiovas-
cular diseases and a therapeutic agent of cardiovascular 
diseases [33]. However, a study from Rosa et  al. found 
that ANP expression was increased in spontaneously 
hypertensive rats with diabetes mellitus [34]. ANP might 
serve as an important molecule that regulated cardiovas-
cular and metabolic homeostasis [33]. It is possible that 
ANP expression may differ in different stages of disease.
At the same time, we detected decreased corin and 
ANP levels in DCM rats at 12, 16, 20, 33  weeks. Con-
sistent with this, corin and ANP levels were significantly 
reduced after neonatal cardiomyocytes and H9c2 car-
diomyoblasts were treated with high glucose for 36, 48, 
60 h. Corin and ANP expression was decreased with high 
glucose treatment in a time-dependent manner, which 
indicated that the changes of corin and ANP levels were 
associated with the course of diseases. With these results, 
we conclude that corin participates in the development of 
DCM through activation of pro-ANP.
Relationship between lack of corin and endothelial 
dysfunction in the development of diabetic 
cardiomyopathy
Endothelial dysfunction is considered as the pathologi-
cal basis in cardiovascular diseases and a contributing 
factor in the progression of diabetic complications [35]. 
Endothelial dysfunction and vascular remodeling were 
important in the development of diabetic cardiomyopa-
thy [13, 36]. Here, we found that the lack of corin inhib-
ited endothelial migration in vitro by the scratching test. 
Fig. 6 Defect of corin was associated with endothelial dysfunction. a The wound healing scratch assay showed the effect of culture supernatants 
of H9c2 cardiomyoblasts transfected Corin-siRNA or NC-siRNA on EA.hy926 cells migration at 0 and 24 h. Bar 250 μm. b, c Reduced capillary and 
arteriole densities in DCM rat myocardium were detected by confocal fluorescence microscope. Capillary and arteriole densities were stained by 
iso-lectin B4 (green) in rat hearts, nuclei were stained with Dapi (blue). Bar 50 μm (n = 5 to 6 rats for each group). For quantification, 4 or 5 randomly 
selected fields from each rat myocardial tissue under ×400 magnification were analyzed. Data are presented as mean ± SD. *P < 0.05 versus Ctrl
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At the same time, decrease of microvessel density in 
DCM rat myocardium indicated that the capillary and 
arteriole endothelium were impaired. Hence, we con-
cluded that the reduced microvessel density was asso-
ciated with decrease of corin in DCM. Similar findings 
were reported in our previous study that in corin knock-
out mice, uterine spiral artery remodeling was impaired, 
causing pre-eclampsia [14]. In fact, corin activates pro-
ANP to ANP. ANP was shown to regulate endothelial 
cell growth and migration [32], which were important 
in angiogenic processes [37]. Another study demon-
strated that endogenous ANP played a key role in vas-
cular remodeling in ischemic tissue [38]. As shown in 
our paper, corin and ANP expression were decreased in 
DCM suggesting that corin deficiency led to endothelial 
dysfunction and vascular remodeling, which promoted 
the development of DCM. This is a new molecular mech-
anism in vascular remodeling of DCM.
In fact, there are several limitations in our study. Firstly, 
we could not exclude the effects of other factors on 
DCM due to the lack of corin knockout animal model. 
Secondly, additional studies are necessary to confirm 
whether corin improves DCM through other signaling 
pathway. Finally, corin activator (PCSK6) has been iden-
tified recently [25]. Further studies are required to con-
firm whether PCSK6 is involved in DCM. Nevertheless, 
our study may provide an important new insight into the 
pathogenesis of diabetic cardiomyopathy.
Conclusions
Taken together, we made a significant new finding that 
cardiac corin and ANP levels were downregulated in 
DCM. Lack of corin prevented H9c2 cardiomyoblasts 
proliferation and suppressed endothelial migration 
in  vitro. These data demonstrate that corin plays an 
important role in cardioprotection by activating pro-
ANP pathway in DCM and corin deficiency leads to 
endothelial dysfunction and vascular remodeling. These 
findings also indicate that corin can be used as a new 
therapeutic strategy for DCM.
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